M A Carducci
Overview
Explore the profile of M A Carducci including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
1304
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mandl A, Jasmine S, Krueger T, Kumar R, Coleman I, Dalrymple S, et al.
bioRxiv
. 2024 Feb;
PMID: 38328141
Statement Of Significance: Neuroendocrine prostate cancer presents a clinical challenge due to the lack of effective treatments. Our research demonstrates that bomedemstat, a potent and selective LSD1 inhibitor, effectively combats...
2.
Hamid A, Huang H, Wang V, Chen Y, Feng F, Den R, et al.
Ann Oncol
. 2021 Jun;
32(9):1157-1166.
PMID: 34129855
Background: The phase III CHAARTED trial established upfront androgen-deprivation therapy (ADT) plus docetaxel (D) as a standard for metastatic hormone-sensitive prostate cancer (mHSPC) based on meaningful improvement in overall survival...
3.
Harshman L, Drake C, Haas N, Manola J, Puligandla M, Signoretti S, et al.
Kidney Cancer
. 2018 Oct;
1(1):31-40.
PMID: 30334002
In 2017, there is no adjuvant systemic therapy proven to increase overall survival in non-metastatic renal cell carcinoma (RCC). The anti-PD-1 antibody nivolumab improves overall survival in metastatic treatment refractory...
4.
Armstrong A, Antonarakis E, Taplin M, Kelly W, Beltran H, Fizazi K, et al.
Ann Oncol
. 2017 Nov;
29(1):23-25.
PMID: 29088323
No abstract available.
5.
Paller C, Pantuck A, Carducci M
Prostate Cancer Prostatic Dis
. 2017 Apr;
20(3):265-270.
PMID: 28440320
Background: Preclinical studies showing that pomegranate juice and its components inhibit prostate cancer led to multiple clinical trials to determine whether pomegranate products could slow the growth of prostate cancer....
6.
Armstrong A, Halabi S, Healy P, Lee W, Koontz B, Moul J, et al.
Prostate Cancer Prostatic Dis
. 2016 Jan;
19(1):100-6.
PMID: 26754260
Background: In men with high Gleason PC and rapid PSA progression after surgery, failure rates remain unacceptably high despite salvage radiation. We explored a novel multimodality approach of docetaxel with...
7.
Nakazawa M, Lu C, Chen Y, Paller C, Carducci M, Eisenberger M, et al.
Ann Oncol
. 2015 Jun;
26(9):1859-1865.
PMID: 26117829
Background: We previously showed that pretreatment detection of androgen receptor splice variant-7 (AR-V7) in circulating tumor cells (CTCs) from men with castration-resistant prostate cancer is associated with resistance to abiraterone...
8.
Armstrong A, Haggman M, Stadler W, Gingrich J, Assikis V, Polikoff J, et al.
Clin Cancer Res
. 2013 Nov;
19(24):6891-901.
PMID: 24255071
Purpose: Tasquinimod (Active Biotech) is an oral immunomodulatory, anti-angiogenic, and anti-metastatic agent that delayed metastatic disease progression in a randomized placebo-controlled phase II trial in men with metastatic castration-resistant prostate...
9.
Paller C, Olatoye D, Xie S, Zhou X, Denmeade S, Eisenberger M, et al.
Prostate Cancer Prostatic Dis
. 2013 Oct;
17(1):28-33.
PMID: 24100642
Background: PSA doubling time (PSADT) is an attractive intermediate end point for assessing novel therapies in biochemically recurrent prostate cancer (BRPC). This study explores whether PSADT calculations are influenced by...
10.
Schweizer M, Lin J, Blackford A, Bardia A, King S, Armstrong A, et al.
Prostate Cancer Prostatic Dis
. 2013 Aug;
16(4):357-61.
PMID: 23958896
Background: Preclinical drug screens identified disulfiram as a potent in vitro inhibitor of prostate cancer (PCa) cell growth. Although many mechanisms for its anticancer activity have been proposed, tumor suppressor...